ADRO - Aduro BioTech, Inc.
| Previous Close | 1.3500 |
| Open | 1.3400 |
| Bid | 0.0000 x 1100 |
| Ask | 1.5000 x 3200 |
| Day's Range | 1.3250 - 1.3700 |
| 52 Week Range | 1.2200 - 8.1000 |
| Volume | 77,428 |
| Avg. Volume | 453,407 |
| Market Cap | 107.388M |
| Beta (3Y Monthly) | 0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1500 |
| Earnings Date | Aug 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Simply Wall St.
Who Has Been Selling Aduro BioTech, Inc. (NASDAQ:ADRO) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Zacks
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
- GlobeNewswire
Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
BERKELEY, Calif., Aug. 01, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
- Zacks
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
- Zacks
Aduro Stock Crashes After ASCO Updates on Cancer Candidate
Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.
- GlobeNewswire
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis. Aduro’s ADU-S100 (MIW815), a novel STING pathway activator, is being evaluated in combination with Novartis’ spartalizumab (PDR001), an investigational anti-PD-1 monoclonal antibody, in patients with advanced solid tumors or lymphomas.
- American City Business Journals
Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
Bay Area companies are gearing up for ASCO, HCP's Brisbane biotech building is on the rise and more in our Health Care Digest.
- GlobeNewswire
Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host and webcast an investor event on Monday, June 3, 2019 at 6:30 am CDT in Chicago, IL. Guest speaker, Dr. Funda Meric-Bernstam of MD Anderson Cancer Center, is a principal investigator for the Phase 1 study of STING pathway activator ADU-S100 (MIW815) in combination with spartalizumab (PDR001), Novartis’ investigational anti-PD-1 monoclonal antibody, in patients with advanced/metastatic solid tumors or lymphomas.
- GlobeNewswire
Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided an update on its clinical development programs for BION-1301, a first-in-class humanized IgG4 monoclonal antibody that fully blocks APRIL binding to both the BCMA and TACI receptors.
- Zacks
Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates
Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.
- Zacks
Aduro Biotech (ADRO) Reports Q1 Loss, Misses Revenue Estimates
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
What's in Store for Axsome (AXSM) This Earnings Season?
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
- GlobeNewswire
Aduro Biotech Reports First Quarter 2019 Financial Results
BERKELEY, Calif., May 07, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
- Zacks
Guardant Health (GH) to Report Q1 Earnings: What's in Store?
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
- Zacks
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
- Zacks
Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
- Zacks
What's in the Cards for Perrigo (PRGO) This Earnings Season?
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
- Zacks
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.
- Zacks
What's in Store for Sorrento (SRNE) This Earnings Season?
Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.
- Zacks
PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?
During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.
- Zacks
Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.
- Zacks
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
- Zacks
What's in the Cards for Bausch Health (BHC) Q1 Earnings?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.
